Clinical trials: Neoplastic Cells, Circulating
Solid Tumor, Adult
Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology
Fifteen cohorts will be opened. Each cohort will explore one analysis method and/or tumoral type. Up to 50 patient can be included into each cohort.
- Trial name
- CTC-CEC-ADN (NCT02220556)
- Testing
- Blood sampling
- Where
- 3 sites in France
- Volunteers
- 360 people
- Sponsor
- Institut Curie
Metastatic Breast Cancer
Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients
Characterization of the driver mutations in an individual metastatic breast cancer patient is critical for many reasons. Effective targeted therapies require identifying genomic alterations in the tumoral tissue.
- Trial name
- MIRROR (NCT02626039)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Renal Cell Carcinoma
Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma
The purpose of this study is to see if researchers can detect circulating tumor cells (CTC) and circulating endothelial cells (CEC) in the blood.
- Trial name
- NCT01173445
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Kansas
HER2-positive Metastatic Breast Cancer, Ovarian Cancer
Feasibility of a New Technology for Isolating Circulating Tumour Cells
This is a prospective interventional single-site research with a collection of biological samples. The primary objective of the trial is to assess the ability of the "new technology" to isolating circulating tumor cells (CTC) in…
- Conditions
- HER2-positive Metastatic Breast Cancer, Ovarian Cancer, Hormone-resistant Prostate Cancer, Circulating Tumor Cell
- Trial name
- CTC-SMMiL-E (NCT03979339)
- Testing
- Blood sample collection
- Where
- France
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Centre Oscar Lambret
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oral Cancer
Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT
The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment.
- Trial name
- NCT07296250
- Testing
- low-dose oral chemotherapy
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Lung Cancer, Bone Metastases
CTC in Lung Caner Patients With Bone Metastases
1. Evaluate the feasibility of single cell sequencing technology based on three-dimensional bionic capture network; 2. To build a risk prediction model of bone related events based on single cell sequencing; 3.
- Conditions
- Lung Cancer, Bone Metastases, Single Cell Sequencing Technology
- Trial name
- NCT04568291
- Testing
- model treatment, routine treatment
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai 6th People's Hospital
Clear Cell Renal Cancer, Circulating Tumor Cells
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
Circulating tumor cells (CTCs) have prognostic value in several tumor types, and increasing evidence suggests that molecular characterization of CTCs can serve as a "liquid biopsy" to understand and address treatment resistance.
- Conditions
- Clear Cell Renal Cancer, Circulating Tumor Cells, Circulating Endothelial Cells, Prognostic Biomarkers
- Trial name
- NCT02499458
- Testing
- None- observational study
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Cancer Ductal Infiltrating Metastatic
Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer
Evaluation of the use of Circulating tumour Cells to guide chemotherapy from the 3rd line of chemotherapy for metastatic breast cancer.
- Trial name
- CirCé01 (NCT01349842)
- Testing
- Blood sampling, Usual clinical and radiological criteria
- Where
- 7 sites in France
- Volunteers
- 265 people
- Sponsor
- Institut Curie
Melanoma Neoplasms
Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma
the study aims to implement new approaches for the identification of circulating tumor cells and circulating microRNAs, which aim to silence the expression of genes and thus prevent the production of proteins in patients with…
- Trial name
- NCT06863870
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Metastatic Melanoma
Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques
The main objective of this study is to compare results for the detection of circulating melanoma cells (CMC) using CellSearch versus EPISPOT (EPithelial ImmunoSPOT) techniques between a group of patients with metastatic melanoma…
- Trial name
- NCT01558349
- Where
- 2 sites in France
- Volunteers
- 73 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Metastatic Prostate Cancer, CTC
Validation of the Prostate Cancer Assay - Beta+Pivotal
The Prostate Cancer Assay performance of Celsee Diagnostics circulating tumor cell (CTC) analysis system will be validated in patients diagnosed with metastatic prostate cancer.
- Trial name
- VPCA-B+PIV (NCT02742259)
- Testing
- Blood Draw
- Sponsor
- Celsee Diagnostics
Lung Cancer, Relapse/Recurrence
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early…
- Trial name
- NCT06262386
- Testing
- Cisplatin based chemottherapy
- Where
- Taiwan
- Volunteers
- 358 people
- Sponsor
- Chang Gung Memorial Hospital
Urothelial Carcinoma
Circulating Tumor DNA Response In Urothelial Cancer
The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
- Trial name
- NCT07183319
- Testing
- Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Oklahoma
Circulating Tumor Cells
Cancer DNA Screening Pilot Study (CANDACE)
The investigators have developed an assay that can sensitively and specifically detect DNA mutations circulating in human plasma that may be indicators of the presence of a solid tumor.
- Trial name
- CANDACE (NCT02808884)
- Testing
- Circulating tumor DNA assay
- Where
- Canada
- Volunteers
- 1,514 people, healthy volunteers welcome
- Sponsor
- British Columbia Cancer Agency
Epithelial-Mesenchymal Transition, Circulating Tumor Cells
Aspirin on CTCs of Advanced Breast and Colorectal Cancer
The purpose of this study is to determine whether Aspirin could affect the number and subtype of circulating tumor cells of metastatic breast cancer and colorectal cancer.
- Trial name
- ACABC (NCT02602938)
- Testing
- Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Provincial People's Hospital
Neoplastic Cells, Circulating, Pancreatic Cancer
Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality in the United States. The high mortality for these tumors is primarily attributed to the late stage in which most patients are diagnosed, leading to…
- Conditions
- Neoplastic Cells, Circulating, Pancreatic Cancer, Biological Markers
- Trial name
- NCT02974764
- Testing
- No intervention/exposures
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in renal cancer could play an important role in…
- Trial name
- NCT02450448
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Gastric Cancer
Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer
To assess the predictive value of circulating tumor cells (CTCs) for recurrence of advanced gastric cancer after radical resection.
- Trial name
- NCT01848015
- Testing
- detection of CTCs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University
Prostate Cancer
Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer
As prostate cancer progresses, tumor cells dissociate and enter the bloodstream. Considered a "liquid biopsy," these circulating tumor cells (CTC) can show how a patient's cancer evolves and responds to treatments.
- Trial name
- NCT02723526
- Testing
- Blood drawing
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University